Evidence map›Paper›PMID 31497384›Full record

ArticlePeerJ2019

Therapeutic effect of Bacillus Calmette-Guerin polysaccharide nucleic acid on mast cell at the transcriptional level.

Siyu Yan, Runqiu Liu, Manyun Mao, Zhaoqian Liu, Wei Zhang, Yi Zhang, Jie Li, Cong Peng, Xiang Chen

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Uncovering the Mast Cell Response toFrontiers in immunology · 2022
    Review
  6. The Research Progress in Immunotherapy of Tuberculosis.Frontiers in cellular and infection microbiology · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Siyu YanDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Runqiu LiuDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Manyun MaoDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Zhaoqian LiuInstitute of Clinical Pharmacology, Xiangya Hospital, Changsha, China.
Wei ZhangInstitute of Clinical Pharmacology, Xiangya Hospital, Changsha, China.
Yi ZhangJIUZHITANG Medicine Commerce CO, LTD, Changsha, China.
Jie LiDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Cong PengDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiang ChenDepartment of Dermatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiangya Hospital Central South University · CNHunan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic spontaneous urticaria (CSU) is a common and recurrent autoimmune-related disease with unclear pathogenesis. Dysfunction of immune cells, such as T cells, mast cells, and basophils, is involved. Bacillus Calmette-Guerin polysaccharide nucleic acid (BCG-PSN), an immunomodulator partially extracted from BCG, can be used in the combined treatment of CSU with an unknown mechanism.

methodsTo study the therapeutic effect and mechanism of BCG-PSN on CSU, we initially assessed the clinical efficacy in 110 enrolled CSU patients of 4-week antihistamine monotherapy vs. antihistamine plus BCG-PSN combined therapy. Subsequently, to explore the further mechanism of BCG-PSN, the mast cell line RBL-2H3 pretreated with BCG-PSN was used to evaluate the transcriptional expression profiles via lncRNA sequencing. Real time PCR was conducted to validate the candidate gene expression.

resultsWe found no significant difference in treatment efficacy between the BCG-PSN group (71.7%) and the monotherapy group (71.9%). However, the average time of complete relief in the BCG-PSN group was significantly shorter than that in the monotherapy group (36.77 ± 17.33 vs. 51.27 ± 16.80, DISCUSSION: CSU is a chronic, recurrent disease with complex pathogenesis. Mast cells and basophils are the primary target cells of the disease. BCG-PSN decrease the β-HEX release rates and regulated IgE-mediated mast cell activation in RBL-2H3 cells by mediating immune-related gene expression including ERBB4. These findings suggest that BCG-PSN may mediate ERBB4 expression

Indexed as

BCG-PSNChronic spontaneous urticariaCombined therapeutic effectMast cell

Identifiers

PMID31497384
PMCPMC6708377
OpenAlexW2975383428

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.